MAJOR DEPRESSIVE DISORDER:

EVIDENCE-BASED STRATEGIES TO IMPROVE PATIENT OUTCOMES

Lisa Anderson, DNP, APRN, PMHNP-BC; Brayden Kameg, DNP, PMHNP-BC, CARN-AP, CNE



5=Extremely

Confident

INTRODUCTION

- Major depressive disorder (MDD) is a common mood disorder affecting 21% to 30% of the US population at any one time¹
- Each year, more than 49,000 people in the US die by suicide, and an additional 1.7 million people attempt suicide²
- MDD is underdiagnosed and undertreated^{3,4}
- Among patients who do start antidepressant therapy, most do not achieve full remission with initial therapy⁵
- Given the current knowledge and practice gaps in the management of MDD and the availability of established and novel treatment options from various drug classes, there is a need for education targeted toward the NPs that most often treat these patients (ie, primary care providers)

1. Centers for Disease Control and Prevention (CDC). November 8, 2023. https://www.cdc.gov/nchs/covid19/pulse/mental-health.htm tps://www.cdc.gov/suicide/suicide-data-statistics.html. 3. Mitchell AJ et al. Lancet. 2009;374(9690):609-619. 4. Thornicroft G et al. Br J Psychiatry. 2017;210(2):119-124. 5. Rush AJ et al. Am J Psychiatry. 2006;163(11):1905-1917.

OBJECTIVES

The goal was to develop an enduring CE monograph for NPs that addresses knowledge and practice gaps in MDD care through the following LOs:

- Compare new and emerging pharmacologic treatment options for patients with MDD, including initial treatments, and those for patients with an inadequate initial response or treatment-refractory MDD.
- Evaluate the importance of prompt diagnosis of MDD to prevent negative effects on patient quality of life, morbidity, and mortality.
- Measure response to antidepressant treatment to assess if a patient will benefit from alternative or adjunctive interventions.
- Apply evidence-based and guideline-recommended strategies for the individualization of antidepressant treatment options.

DESIGN & METHODS

CE activity and assessments

- The CE activity included an enduring monograph activity (1.0-hr CE credit and 0.5-hr Rx credit), podcast, and patient tool
- Outcomes questions were developed based on LOs, with linkage to the needs assessment and content
- Before the activity, learners self-reported demographic data and answered knowledge and confidence questions (pre-activity responses)
- After the activity, learners answered the same knowledge and confidence questions (post-activity responses) and activity evaluation questions
- A follow-up survey was conducted 60 days after activity completion

Data analysis

- Descriptive statistics were used for demographic and evaluation data
- Differences between pre- and post-activity multiple choice responses and Likert responses were analyzed with Chi-square tests and paired analyses, respectively (significance level, *P* ≤ .05)

RESULTS

REACH & DEMOGRAPHICS

- During the 12-month activity, 11,024 learners registered
- Of the 7963 learners who completed the activity:
- 7113 (89%) were NPs
- 5624 (71%) were certified in family practice
- 985 (12%) were certified in adult/gerontology care
- 3065 (38%) practiced in a primary care or internal medicine setting

~270%

more registrants and completers than estimated

podcast downloads as of January 1, 2024

increase in average percent

pre- to post-activity results


RESULTS


KNOWLEDGE CHANGE

Screening and diagnosis (LO 2)


Pre-activity Post-activity


Pre-activity Post-activity





Initial treatment and response assessment (LOs 1, 3, & 4)






increase in learners able to identify substance use screening as a consideration for a patient with ongoing treatment nonresponse and missed appointments


NOTE: In written feedback, many learners dicated they would have screened for e most commonly chosen incorrect answe s "Switch to an SNRI," which would have n reasonable if substance use screening d already been performed.

Subsequent-line treatment and individualization (LOs 1 & 4)



RESULTS


CONFIDENCE CHANGE



■ Pre-activity (mean, 3.0)

■ Post-activity (mean, 3.9)

Ability to select pharmacotherapy to augment initial therapy for patients with MDD



RESULTS

PLANNED CHANGES & BARRIERS

1=Not At All

Confident

- The proportion of learners who screened/planned to screen for MDD at every visit increased from 48% to 67%
- The most common planned practice changes were consideration of comorbidities when choosing antidepressant therapy (49%), screening with a validated tool (21%), and assessing factors that can impact treatment response (12%)
- 58% of learners identified no barriers to practice changes
- The most common barriers were time constraints (16%) and patient expectations (11%)

RESULTS

FOLLOW-UP SURVEY (N = 70)

~49%

~57%

~58%

were screening for MDD at every visit

used information from the activity for practice site education or process

implemented new tools or practice habits as a result of the activity

CONCLUSIONS

- The program reached the right target audience—primarily NPs in family practice or primary care
- There was a substantial demand for education on the topic of MDD management
- Based on differences between pre- and post-activity results, knowledge increased by a significant 30% (P < .0001)
- Confidence increased significantly in selection of initial and subsequent-line therapy

ACKNOWLEDGEMENTS

This activity was supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc.